Biotechnology

While debates over UN dues persist, American companies quietly secured over $2 billion in UN contracts, turning global initiatives into a major revenue stream.

Biotech firm ReBio Pharma appoints world-renowned expert Prof. Mandeep Sagoo as CMO, accelerating its novel RBP-01 therapy for uveal melanoma into the clinic.

D&D Pharmatech's zabopegdutide shows fast liver improvement independent of weight loss, a key differentiator in the crowded, multi-billion dollar MASH market.

Peer-reviewed data confirms Telix's theranostic approach for advanced prostate cancer, de-risking its Phase 3 trial and setting the stage for a new competitor.

New preclinical data shows atebimetinib outmaneuvers older drugs by hitting cancer hard, then resting. Is this the key to durable tumor control and resilience?

A high-level Dubai summit unites tech, pharma, and policy to combat the GCC's escalating IBD crisis, heralding a new era of AI-driven care and IL-23 therapies.

A Boston biotech is making waves with a novel drug and a rapid-screening platform, a one-two punch designed to eliminate drug-resistant cancer stem cells.

As its lead therapy for NCFB enters clinical trials, Revagenix promotes a seasoned drug developer to steer its patient-centric strategy in the chronic disease market.

San Diego's VivoSim Labs enters China, leveraging AI-powered human tissue models that challenge traditional animal testing and aim for safer, faster drug development.

SOTIO Biotech's European patent win for its immunocytokine SOT201 wasn't just a legal victory; it's a signpost in the fierce race to redefine cancer care.

Lonza licenses its elite ADC tech to Engitix, a biotech targeting the hidden battlefield of the extracellular matrix. A quiet move with loud implications.

A biotech startup is betting it can turn your body into a factory for allergy-fighting cells, aiming to cure diseases, not just treat them. Is this the future?

PolyPid inks a transformative partnership with Azurity for its surgical infection drug, D-PLEX100, securing over $320M and a clear path to market.

Jupiter Neurosciences' $100M deal for a novel MDMA drug signals a major strategic shift, betting on a new era of psychedelic medicine in the U.S.

Avaí Bio's new deal for its Insulinova therapy brings a mysterious, world-class partner to the table, signaling a major step toward a functional cure for diabetes.

The life sciences giant beat expectations with a 60% earnings jump, raising its 2026 forecast. Key drivers include the Masimo deal and a new acquisition plan.

Berlin-based OMEICOS gets a major FDA boost, advancing its novel PMD drug OMT-28 directly to a pivotal Phase 3 trial. A deep dive into the science.

Arcturus Therapeutics heads to the Canaccord Growth Conference to spotlight its advanced mRNA platform, shifting focus from COVID vaccines to rare diseases.

With key hires from Vivodyne and Ferring, Conceivable Life Sciences isn't just staffing up; it's signaling a full-scale assault on the IVF market.

New research reveals how IntraBio's AQNEURSA recalibrates cellular function, a novel mechanism that could revolutionize treatment for a wide range of diseases.